细胞动力科技 CYTK 深 沪
已收盘 02-06 16:00:00 美东时间
62.34
+2.100
+3.49%
华盛通- 最 高62.74
- 今 开61.31
- 成交量 173.67万股
- 最 低 61.00
- 昨 收 60.24
- 总市值 76.22亿
- 52周最高 70.98
- 市盈率 静 --
- 换手率 1.42%
- 52周最低 29.31
- 委 比 61.58%
- 总股本 1.22亿
- 历史最高 110.25
- 量 比 1.03
- 振 幅 2.89%
- 历史最低 0.57
- 每 手 1
- 风险率 12.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $92
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $84 to $92.
02-03 21:09
Cytokinetics EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Common Shares
Cytokinetics EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Common Shares Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics Incorporated, has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: Thi
02-03 05:41
Cytokinetics Announces U.S. Availability Of MYQORZO To Treat Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. MYQORZO was recently approved by the U.S.
01-27 20:39
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX Jan 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, KLA and WEX, on Wednesday. HIGHLIGHTS * IBM IBM.N : JP Morgan raises target price to $312 from $290 * KLA Corp KLAC.O : Deut
01-21 16:26
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $74
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $70 to $74.
01-20 22:49
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted stock options and RSUs to 8 new employees on January 15, 2026, as inducements to employment. The RSUs vest over 3 years, while the stock options vest over 4 years with a 10-year term. The company focuses on developing cardiovascular therapies, with MYQORZO™ approved for obstructive HCM and under review in the EU. Additional pipeline candidates target heart failure.
01-20 21:00
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Cytokinetics' CEO, Robert I. Blum, will present at the 44th J.P. Morgan Healthcare Conference on January 12, 2026. The event will be webcast live and archived for 90 days. Cytokinetics specializes in cardiovascular biopharmaceuticals, focusing on muscle biology to develop treatments for cardiac dysfunction. Its lead product, MYQORZO™ (aficamten), is approved for obstructive hypertrophic cardiomyopathy (HCM) and has received a positive opinion fro...
01-05 21:00
